Your browser is no longer supported. Please, upgrade your browser.
Settings
CRDF Cardiff Oncology, Inc. daily Stock Chart
CRDF [NASD]
Cardiff Oncology, Inc.
Index- P/E- EPS (ttm)-2.12 Insider Own0.40% Shs Outstand9.91M Perf Week6.12%
Market Cap87.90M Forward P/E- EPS next Y-1.06 Insider Trans0.00% Shs Float9.73M Perf Month77.56%
Income-16.60M PEG- EPS next Q-0.24 Inst Own22.40% Short Float5.60% Perf Quarter369.79%
Sales0.30M P/S293.00 EPS this Y66.20% Inst Trans263.28% Short Ratio0.60 Perf Half Y257.94%
Book/sh0.62 P/B7.27 EPS next Y0.90% ROA- Target Price- Perf Year109.77%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.70 - 5.75 Perf YTD263.71%
Dividend- P/FCF- EPS past 5Y44.80% ROI-228.50% 52W High-21.57% Beta1.50
Dividend %- Quick Ratio2.10 Sales past 5Y-2.70% Gross Margin- 52W Low543.37% ATR0.49
Employees14 Current Ratio2.10 Sales Q/Q0.00% Oper. Margin- RSI (14)62.22 Volatility11.53% 12.85%
OptionableNo Debt/Eq0.00 EPS Q/Q59.60% Profit Margin- Rel Volume0.54 Prev Close4.72
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume914.56K Price4.51
Recom2.00 SMA2012.74% SMA5058.09% SMA200160.57% Volume493,209 Change-4.45%
Jun-16-20 08:30AM  
Jun-15-20 08:30AM  
Jun-09-20 08:15AM  
May-29-20 08:30AM  
May-28-20 08:15AM  
May-27-20 08:15AM  
May-19-20 08:15AM  
May-13-20 08:15AM  
Cardiff Oncology, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer; Phase I clinical trial with various chemotherapies and targeted therapeutics, such as Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) used in leukemias, lymphomas, and solid tumor cancers. It primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.